Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
Continued Progress Across Pipeline Supports Expanded Therapeutic OpportunitiesSOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. NASDAQ:ARTL (“Artelo” or the “Company”), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop t…